Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

AC Immune S.A. (Nasdaq: ACIU)

AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments. *

 

Period Start 2003-02-01 established
Products Industry CNS drug (neurological drug)
  Industry 2 crenezumab
Person Person Roberts, Christopher (Chris) (AC Immune 202401– promoted to CFO joined 2019)
     
Region Region Lausanne VD
  Country Switzerland
  City 1015 Lausanne VD
  Tel +41-21-3459121
    Address record changed: 2024-01-05
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency CHF
  Annual sales 14,801,000 (revenue, total, consolidated (2023) 2023-12-31)
  Profit -54,233,000 (2023-12-31)
  Cash 78,494,000 (2023-12-31)
     
    * Document for »About Section«: AC Immune S.A.. (6/27/23). "Press Release: AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease". Lausanne.
     
   
Record changed: 2024-09-17

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for AC Immune S.A. (Nasdaq: ACIU)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x300px




» top